Treatment-free remission is now regarded as a primary aim of patients with long-term chronic myeloid leukemia (CML).
Starting with the approval of imatinib in 2001, the effectiveness of tyrosine kinase inhibitors (TKIs) has resulted in significant improvements in outcomes for CML patients, and with that success has come a focus on discontinuing treatment in patients when appropriate.
Results from trials such as the DADI (Dasatinib Discontinuation) and the STIM (Stop Imatinib) trials suggest this approach is feasible, and the National Comprehensive Cancer Network has modified its guidelines by incorporating TKI discontinuation in appropriately selected patients.
